Coherus BioSciences Inc (CHRS) Stock Analysis

Coherus BioSciences Inc (CHRS) is a publicly traded company in the HEALTHCARE sector. It trades at $1.52, carries a market capitalization of $242.17M. This page summarizes the public market data, fundamentals, and frequently asked questions for CHRS, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $1.52
• Market Cap: $242.17M
• EPS: $-1.42
• 52-Week High: $2.62
• 52-Week Low: $0.71

Market Sentiment

Coherus BioSciences Inc currently has a Bullish sentiment score of 0.23.

About Coherus BioSciences Inc

Coherus BioSciences Inc. is an innovative biopharmaceutical company focused on developing and commercializing biosimilars and cutting-edge immuno-oncology therapies, primarily in the U.S. market. Headquartered in Redwood City, California, Coherus is dedicated to expanding patient access to high-quality biologic therapies while effectively lowering healthcare expenses. With a strong product pipeline and strategic partnerships, the company is well-positioned to meet the increasing demand for co...

GNG Research Analysis

GNG Research scores Coherus BioSciences Inc (CHRS) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for CHRS.

Frequently Asked Questions

Does CHRS pay dividends?

Coherus BioSciences Inc (CHRS) does not currently pay a regular dividend.

What is CHRS's market cap?

Coherus BioSciences Inc (CHRS) has a market capitalization of $242.17M with a current stock price of $1.52.